Cargando…
An open-label trial of memantine in treatment-resistant obsessive-compulsive disorder
BACKGROUND: Obsessive-compulsive disorder (OCD) is often refractory to treatment. Glutamatergic neurotransmission modulating agents like memantine, an N-methyl-D-aspartate receptor open channel blocker (antagonist), has been reported to be beneficial in OCD. MATERIALS AND METHODS: Twelve subjects of...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4085808/ https://www.ncbi.nlm.nih.gov/pubmed/25013317 http://dx.doi.org/10.4103/0972-6748.132930 |
_version_ | 1782324709539446784 |
---|---|
author | Bakhla, Ajay Kumar Verma, Vijay Soren, Subhas Sarkhel, Sujit Chaudhury, Suprakash |
author_facet | Bakhla, Ajay Kumar Verma, Vijay Soren, Subhas Sarkhel, Sujit Chaudhury, Suprakash |
author_sort | Bakhla, Ajay Kumar |
collection | PubMed |
description | BACKGROUND: Obsessive-compulsive disorder (OCD) is often refractory to treatment. Glutamatergic neurotransmission modulating agents like memantine, an N-methyl-D-aspartate receptor open channel blocker (antagonist), has been reported to be beneficial in OCD. MATERIALS AND METHODS: Twelve subjects of OCD who had been on various medications for over 5 years, but were poor responders, were enrolled for a 12-week open-label trial with fixed dose trial of memantine as an augmenting agent. The OCD symptoms and adverse effects of the drug were monitored. RESULTS: Out of 12 subjects, eight had clear benefit, with reduction of 25% or more on Yale-Brown Obsessive-Compulsive Scale, and there were no side-effects with the medication, CONCLUSION: Memantine may be beneficial for treatment-resistant OCD as an augmenting agent. |
format | Online Article Text |
id | pubmed-4085808 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-40858082014-07-10 An open-label trial of memantine in treatment-resistant obsessive-compulsive disorder Bakhla, Ajay Kumar Verma, Vijay Soren, Subhas Sarkhel, Sujit Chaudhury, Suprakash Ind Psychiatry J Original Article BACKGROUND: Obsessive-compulsive disorder (OCD) is often refractory to treatment. Glutamatergic neurotransmission modulating agents like memantine, an N-methyl-D-aspartate receptor open channel blocker (antagonist), has been reported to be beneficial in OCD. MATERIALS AND METHODS: Twelve subjects of OCD who had been on various medications for over 5 years, but were poor responders, were enrolled for a 12-week open-label trial with fixed dose trial of memantine as an augmenting agent. The OCD symptoms and adverse effects of the drug were monitored. RESULTS: Out of 12 subjects, eight had clear benefit, with reduction of 25% or more on Yale-Brown Obsessive-Compulsive Scale, and there were no side-effects with the medication, CONCLUSION: Memantine may be beneficial for treatment-resistant OCD as an augmenting agent. Medknow Publications & Media Pvt Ltd 2013 /pmc/articles/PMC4085808/ /pubmed/25013317 http://dx.doi.org/10.4103/0972-6748.132930 Text en Copyright: © Industrial Psychiatry Journal http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Bakhla, Ajay Kumar Verma, Vijay Soren, Subhas Sarkhel, Sujit Chaudhury, Suprakash An open-label trial of memantine in treatment-resistant obsessive-compulsive disorder |
title | An open-label trial of memantine in treatment-resistant obsessive-compulsive disorder |
title_full | An open-label trial of memantine in treatment-resistant obsessive-compulsive disorder |
title_fullStr | An open-label trial of memantine in treatment-resistant obsessive-compulsive disorder |
title_full_unstemmed | An open-label trial of memantine in treatment-resistant obsessive-compulsive disorder |
title_short | An open-label trial of memantine in treatment-resistant obsessive-compulsive disorder |
title_sort | open-label trial of memantine in treatment-resistant obsessive-compulsive disorder |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4085808/ https://www.ncbi.nlm.nih.gov/pubmed/25013317 http://dx.doi.org/10.4103/0972-6748.132930 |
work_keys_str_mv | AT bakhlaajaykumar anopenlabeltrialofmemantineintreatmentresistantobsessivecompulsivedisorder AT vermavijay anopenlabeltrialofmemantineintreatmentresistantobsessivecompulsivedisorder AT sorensubhas anopenlabeltrialofmemantineintreatmentresistantobsessivecompulsivedisorder AT sarkhelsujit anopenlabeltrialofmemantineintreatmentresistantobsessivecompulsivedisorder AT chaudhurysuprakash anopenlabeltrialofmemantineintreatmentresistantobsessivecompulsivedisorder AT bakhlaajaykumar openlabeltrialofmemantineintreatmentresistantobsessivecompulsivedisorder AT vermavijay openlabeltrialofmemantineintreatmentresistantobsessivecompulsivedisorder AT sorensubhas openlabeltrialofmemantineintreatmentresistantobsessivecompulsivedisorder AT sarkhelsujit openlabeltrialofmemantineintreatmentresistantobsessivecompulsivedisorder AT chaudhurysuprakash openlabeltrialofmemantineintreatmentresistantobsessivecompulsivedisorder |